Michiro Susa

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Alendronate inhibits growth of high-grade chondrosarcoma cells
    Michiro Susa
    Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan
    Anticancer Res 29:1879-88. 2009
  2. ncbi Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 9:399. 2009
  3. ncbi Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS ONE 5:e10764. 2010
  4. ncbi Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
    Keinosuke Ryu
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 10:187. 2010
  5. ncbi Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis
    Keinosuke Ryu
    Department of Orthopedic Surgery, Massachusetts General Hospital, Center for Sarcoma and Connective Tissue Oncology, 55 Fruit St Jackson 1115, Boston, Massachusetts 02114, USA
    J Orthop Res 28:971-8. 2010
  6. ncbi Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking
    Michiro Susa
    Department of Orthopaedic Surgery, and SarcomaBiology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 9:3342-50. 2010
  7. ncbi MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 10:1337-45. 2011
  8. ncbi Nanoparticles: a promising modality in the treatment of sarcomas
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Pharm Res 28:260-72. 2011
  9. ncbi Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Lett 293:220-9. 2010
  10. ncbi Anaplastic transformation of follicular thyroid carcinoma in a metastatic skeletal lesion presenting with paraneoplastic leukocytosis
    Robert Nakayama
    Department of Orthopedic Surgery, Keio University, Shinjuku ku, Tokyo, Japan
    Thyroid 22:200-4. 2012

Collaborators

Detail Information

Publications15

  1. ncbi Alendronate inhibits growth of high-grade chondrosarcoma cells
    Michiro Susa
    Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan
    Anticancer Res 29:1879-88. 2009
    ..Bisphosphonates inhibit growth of various cell types, including cancer cells and perhaps chondrosarcoma...
  2. ncbi Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 9:399. 2009
    ....
  3. ncbi Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS ONE 5:e10764. 2010
    ..However, for patients who progress after chemotherapy, its effectiveness diminishes due to the emergence of multi-drug resistance (MDR) after prolonged therapy...
  4. ncbi Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
    Keinosuke Ryu
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 10:187. 2010
    ....
  5. ncbi Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis
    Keinosuke Ryu
    Department of Orthopedic Surgery, Massachusetts General Hospital, Center for Sarcoma and Connective Tissue Oncology, 55 Fruit St Jackson 1115, Boston, Massachusetts 02114, USA
    J Orthop Res 28:971-8. 2010
    ..Our results suggest that Stat3 may be a prognostic indicator and potential therapeutic target for osteosarcoma. Blocking the pathway of Stat3 may lead to develop new therapeutic strategies against osteosarcoma...
  6. ncbi Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking
    Michiro Susa
    Department of Orthopaedic Surgery, and SarcomaBiology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 9:3342-50. 2010
    ..In conclusion, our results suggest that osteosarcoma cell proliferation and survival are dependent on GAK. These findings may lead to the development of new therapeutic options for osteosarcoma...
  7. ncbi MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 10:1337-45. 2011
    ..Restoring miR-199a-3p's function may provide therapeutic benefits in osteosarcoma...
  8. ncbi Nanoparticles: a promising modality in the treatment of sarcomas
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Pharm Res 28:260-72. 2011
    ..In this review, we will discuss the application of nanoparticles for improving the treatment of sarcoma patients...
  9. ncbi Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Lett 293:220-9. 2010
    ..The development of more potent inhibitors that target PLK1 may open doors to a new range of anti-cancer strategies in osteosarcoma...
  10. ncbi Anaplastic transformation of follicular thyroid carcinoma in a metastatic skeletal lesion presenting with paraneoplastic leukocytosis
    Robert Nakayama
    Department of Orthopedic Surgery, Keio University, Shinjuku ku, Tokyo, Japan
    Thyroid 22:200-4. 2012
    ..Anaplastic transformation of differentiated thyroid carcinoma (DTC) is a rare event with a poor clinical outcome. It usually occurs in the primary site or in regional lymph nodes, but rarely in distant metastatic lesions...
  11. ncbi Detection of HEY1-NCOA2 fusion by fluorescence in-situ hybridization in formalin-fixed paraffin-embedded tissues as a possible diagnostic tool for mesenchymal chondrosarcoma
    Robert Nakayama
    Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan
    Pathol Int 62:823-6. 2012
    ..The current study adds further support for the use of HEY1-NCOA2 fusion as a valid diagnostic marker for MC...
  12. ncbi Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer
    Yuqi Guo
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 16:5759-69. 2010
    ..We then looked for enhancing paclitaxel sensitivity in multidrug-resistant ovarian cancer cell lines...
  13. ncbi Metastatic patterns of myxoid/round cell liposarcoma: a review of a 25-year experience
    Naofumi Asano
    Department of Orthopaedic Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Sarcoma 2012:345161. 2012
    ..027). 3 cases with pulmonary metastatic lesions were all diagnosed as high grade. In conclusion, large size and low histological grade were significantly associated with extrapulmonary metastasis...
  14. ncbi Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay
    Michiro Susa
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Biomol Screen 15:287-96. 2010
    ..The use of NSC77037 to restore sensitivity to chemotherapy or to prevent resistance could be a potential treatment strategy for cancer patients...
  15. ncbi Reconstruction modality based on the spare part concept for massive soft tissue defects following oncological hemipelvectomy
    Takeshi Morii
    Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    J Orthop Sci 14:192-7. 2009
    ..Recent innovations in plastic surgery have resulted in the development of novel reconstruction modalities based on "the spare part concept," applying tissues from amputated limbs...